Amanta Healthcare Ltd Share Price

Pharmaceuticals - Indian - Bulk Drugs & Formln M/SNSE
₹222.37
-16.71-6.99% (1D)
As on 20 Nov 2026 at 15:59
As of 20 Nov 2026 at 15:59, Amanta Healthcare Ltd is trading at ₹222.37. The 52-week range stands at ₹92.00–₹245.70, with a market cap of ₹868.22 crore. At a P/E of 47.37 and a dividend yield of 0.00%, it is a small-cap stock in the Pharmaceuticals sector.

AMANTA Price Chart

Market Cap
₹868.22 Cr
PE Ratio
47.37
ROCE
10.74%

Amanta Healthcare Ltd Performance

Amanta Healthcare Ltd Fundamentals

Know More
Market Cap₹868.22 Cr
ROE8.04%
P/E Ratio (TTM)47.37
EPS (TTM)₹4.72
P/B Ratio3.81
Dividend Yield0.00%
Industry P/E91.72
Book Value₹58.75
Debt to Equity0.89
Face Value₹10

Amanta Healthcare Ltd Shareholding Pattern

Know More
Promoter63.8%
Foreign Institutions0.1%
Mutual Funds5.1%
Domestic Institutions7.1%
Public23.9%

Amanta Healthcare Ltd Financial Statements

Know More
No data for this view.

Amanta Healthcare Ltd Peer Comparison

Know More
StocksLTP(₹)Market Cap(Cr)52 Week Low-High(₹)
Sun Pharmaceutical Industries Ltd
₹1,885.10
-14.90(-0.78%)
4,52,298.61,583.7 - 2,046.9
Torrent Pharmaceuticals Ltd
₹4,698.80
87.80(+1.90%)
1,78,727.33,672.3 - 5,250.0
Dr Reddys Laboratories Ltd
₹1,390.50
-10.40(-0.74%)
1,16,144.51,101.0 - 1,414.9
Cipla Ltd
₹1,414.95
-3.55(-0.25%)
1,14,312.11,165.7 - 1,539.7
Lupin Ltd
₹2,010.00
11.20(+0.56%)
91,915.91,892.9 - 2,529.5

About Amanta Healthcare

Amanta Healthcare Limited was originally incorporated on December 21, 1994 as Marck Parenterals (India) Limited with RoC, Gujarat, at Ahmedabad by converting the existing Partnership Firm 'Marck Parenterals (India)' on January 06, 1995. The Company's name was changed to 'Marck Biosciences Limited' on November 2, 2005 and further to 'Amanta Healthcare Limited' w.e.f. June 24, 2014. vide a fresh Certificate of Incorporation issued by the Registrar of Companies, Gujarat. Amanta Healthcare Limited is a pharmaceutical company engaged in developing, manufacturing and marketing a diverse range of sterile liquid products - parenteral products, packed in plastic container with Aseptic Blow-Fill-Seal (ABFS) and Injection Strech Blow Moulding (ISBM) technology. The Company manufacture large volume parenterals (LVPs) and small volume parenterals (SVPs) in six therapeutic segments. In addition to that, it also manufacturer medical devices. It manufacture fluid therapy - (IV Fluid), formulations, diluents, ophthalmic, respiratory care and irrigation solutions in therapeutic segment and products like irrigation, first-aid solution, eye lubricants etc. in medical device segment. The Company introduced Large Volume Parenterals (LVP) project for Formulations, Fluid Therapy & Irrigation Solution in year 1997; and started the L-1 in Block A in 1998. It launched a specialised production line 'LVP Line II' for the manufacture of Large Volume Parenterals in Kheda District of Gujarat in 2002. Further, it launched a specialised production line 'SVP Line I' for the manufacture of Small Volume Parenterals in Kheda, Gujarat in 2005, launched L-III Large Volume Parenterals Facility for 500 ml products in Block -A in 2007; launched a specialised production line 'SVP line II' for the manufacture of Small Volume Parenterals in Gujarat in 2008. Following the approval from National Company Law Tribunal, Ahmedabad, in October 2018, Marck Remedies Private Limited (MRPL) got merged with the Company through the Scheme of Amalgamation and the entire undertaking of MRPL was transferred to the Company as a going concern effective from April 1, 2017. In consideration of the transfer of MRPL's undertaking, 1 fully paid-up Equity Share of Rs 10 of the Company was issued and allotted for every 38 equity shares of Rs 10 each held in MRPL by their respective shareholders. Later on, the Company launched a specialised production line 'SteriPort -Debottlenecking' in 2021 and is currently manufacturing out of seven (7) active production lines including SVP and LVP in 2024. The Company launched the initial public offer by allotting 1,00,00,000 equity shares having the face value of Rs 10 each raising funds of Rs 126 Crore on 3 September, 2025. The Company launched Linezolid I.V. Injection in FY 2025.

Parent Organisation—
Founded1994
Managing DirectorBhavesh Patel
NSE SymbolAMANTA

Amanta Healthcare Ltd Resistance and Support levels

R3247.11R2243.54R1241.33S1234.18S2231.97S3228.39222.37

Amanta Healthcare Ltd Technicals

Current Price
₹222.37 ₹16.71 (-6.99%)
Bearish
2
Bullish
10
  • 20 Day7.2%
  • 50 Day14.9%
  • 100 Day22.9%
  • 200 Day37.7%

Amanta Healthcare Ltd Latest News

View More
03 NOV 2026 | Tuesday
Amanta Healthcare confirms no deviation in Rs 126 crore IPO fund utilization
26 OCT 2026 | Monday
Amanta Healthcare to review quarterly, half-year results at board meeting November 3
06 OCT 2026 | Tuesday
Amanta Healthcare confirms securities handling compliance with MUFG Intime India
24 SEPT 2026 | Thursday
Amanta Healthcare closes securities trading window ahead of financial results release
16 SEPT 2026 | Wednesday
Amanta Healthcare shareholders approved director and auditor appointments at their annual meeting
05 AUG 2026 | Wednesday
Amanta Healthcare reports Rs 68.8 crore revenue, profit after tax declines year-over-year
05 AUG 2026 | Wednesday
Amanta Healthcare appoints Nilesh Punjabi as Senior Management Personnel, effective August 5, 2026
29 JUL 2026 | Wednesday
Amanta Healthcare to review quarterly results at board meeting on August 5, 2026

2026

Quarterly ResultRelease dateCheck Latest financial
Quarterly ResultRelease dateCheck Latest financial
Board MeetingAnnounced
Quarterly ResultRelease dateCheck Latest financial

Frequently asked questions

The share price of Amanta Healthcare Ltd is ₹222.37 as of 20 Nov 2026 at 15:59.

Not sure where to start?

Book a free 30-minute consultation with our investment experts today!

Invest Now